HSCA Comments to EPA on Proposal to Reduce Ethylene Oxide Emissions (EtO) from Commercial Sterilization Facilities and Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Environmental Protection Agency (EPA) on ethylene oxide (EtO).
Please find comments regarding the proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category here.
Please find comments regarding the proposed interim registration review decision and draft risk assessment addendum for ethylene oxide (EtO) here.
Lear MoreHSCA Response to FDA Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Draft Guidance
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), we appreciate the opportunity to comment on the Food and Drug Administration’s (FDA) draft guidance, “Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act.”
Click here to read the full response.
Lear MoreHSCA Comments on FDA Draft Guidance for Drug Supply Chain Security Act (DSCSA) Standards
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), we appreciate the opportunity to comment on the U.S. Food and Drug Administration’s (FDA’s) revised draft guidance, “DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry.”
Click here to read the full comments.
Lear MoreHSCA Comments on FDA “Risk Management Plans to Mitigate the Potential for Drug Shortages” Draft Guidance
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), we appreciate the opportunity to comment on the Food and Drug Administration’s (FDA) “Risk Management Plans to Mitigate the Potential for Drug Shortages” draft guidance.
Click here to read the full comments.
Lear MoreHSCA Comments to FDA Regarding FDA’s List of Public Health Focused Essential Medicines
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Food and Drug Administration (FDA) regarding FDA’s recently published list of essential medicines, medical countermeasures (MCM), and their critical inputs. HSCA and our member companies are committed to ensuring continued patient access to critical medical products.
Click here to read the full comments.
Lear More